Replies to post #231894 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"what are the differences between what he said and others have posted about conversations with CEO?"

To my knowledge there has only been one other "conversation" with the CEO reported. You shouldn't need my help, but I'll make it easy for you.

Posted on 6/16:

His responses in bold:

Shareholders need to know what is happening with the company, given the unexplained problem with getting Prurisol results, We expect to update shareholders shortly. The anticipated sequence of news will be a) Data Lock, and b) thereafter, top-line results.

the toxic capital raise, We sold stock at a fixed price. Albeit low but we needed funds for production of Brilacidin for further studies and other clinical trial payables.

and lack of BTD or deal for Brlacidin-OM despite "excellent" results and saying negotiations were underway. Please anticipate our update as all this is being worked on.

The growing concern is that the company may have misled investors and fumbled the Prurisol trial. The trial will be unblinded shortly. It's a function of company resources allocated to each product.

6/22:

Per Leo - (he acknowledges the house is on fire but of course offers no solution to putting it out)

Of course we are concerned about the stock price. As stated in our recent 10-Q, we are moving forward with partnering discussions. These things take time. In addition, we are expecting Prurisol data lock by our CRO; new batches of Brilacidin (Evonik); and communicating with FDA on OM. As soon as funds are available for Kevetrin we expect to complete the tox bridging study and get right back into the clinic.
Yesterday a report came out addressing the potential size of the OM market, Diamond Equity Research Initiates Coverage on Oragenics Inc. I encourage you to read it and see the potential need and size of the OM market.
https://globenewswire.com/news-release/2018/06/20/1527305/0/en/Diamond-Equity-Research-Initiates-Coverage-on-Oragenics-Inc-NYSE-OGEN-with-a-Valuation-of-3-50-Per-Share.html


The OM results we achieved are outstanding. The market size and yearly profits that are possible with an approved OM drug are multiples of our market cap. We are trying as hard as we can and as fast as we can, to get there.

Regarding the raise at 25 cents we needed and used the funds to pay the CRO's and start the process for the manufacture of Brilacidin for the next clinical trials.

I think I reproduced those accurately. I've made my comments in a previous post(s) and I doubt that anyone wants to hear them twice.